BioSpace News Archive

The system is scheduled to be installed at Sylvester, part of the University of Miami Health System, in early 2019 and begin patient treatments in the first half of 2020.

The Company appoints Philip Wills, PhD, as CCO, John Conner as CMO, and William “Bill” Thomas, Jr., PhD, as CSO, and hires Randy Henrickson as VP of Manufacturing and Dermot McCaul as VP of Information Technology.

Rice University scientists have effectively quenched a debate over the mechanism behind a fluorescent biosensor that monitors neurons by sensing changes in voltage.

Dr. Mari is a renowned expert of clinical research on Parkinson’s disease and movement disorders, who is willing to offer his guidance on GB Sciences’ Parkinson’s disease therapy program.

The current Cancer Discovery article highlights how liquid biopsy techniques, which apply genomic sequencing of circulating DNA isolated from a small vial of blood, can effectively detect cellular mutations in colorectal cancer patients.

CorInnova Inc., an emerging medical device company developing breakthrough technology for the treatment of Heart Failure, announced today that it has been selected to present at the Society for Thoracic Surgeons (STS) / American Association for Thoracic Surgery (AATS) Tech-Con 2018 event to be held this coming Saturday, Jan. 27, in Fort Lauderdale, Fla.

The study examined major bleeding and stroke rates in NVAF patients who had initiated treatment with Pradaxa compared to those treated with rivaroxaban or apixaban.

The Sales and Repurchase Agreement allows the Company to sell its STERIZONE VP4 Sterilizers and associated products and services directly into the United States and Canada.

The broad protection of these patents opens doors to partnerships in the world’s second- and third-largest pharmaceutical markets.

This new partnership further expands Synpromics’ activities in the cell and gene therapy sector, as it builds on its strategy of establishing partnerships with leading academics in the UK to integrate its technology into the next generation of gene-based medicines.